Quintrigen, a subsidiary of BioReaders, will attend ‘p53’ It was announced on the 16th that the research results of anticancer drugs were selected for the presentation.
Professor Varda Rotor and Professor Mosher Oren of the Weisman Institute will be presenters. p53 is a cancer suppressor gene that repairs or eliminates deoxyribonucleic acid that can be transformed into cancer cells. If the p53 gene is mutated, it loses its anticancer function, which is a risk factor for cancer.
He said that abnormalities in the p53 gene were found in more than 50% of cancer patients. Quintrigens p53 anticancer drug is a peptide-based drug. It acts specifically on the p53 mutant protein. It is a mechanism that converts the three-dimensional structure of a protein twisted by mutation to normal, restores anticancer function, and kills cancer cells.
Quintrigen is an Israeli joint venture in which Bioreaders holds 70% and Yeda, the technology holding company of Israels Weisman Research Institute, holds 30%. Weisman Research Institute possesses the p53 original technology developed by Professor Rotor and Professor Oren.
Quintrigen selected the final drug for clinical entry at the end of last year after two years of drug optimization research led by two professors. A Quintrigen official said that a number of multinational pharmaceutical companies are expected to attend the presentation of the anticancer efficacy of p53 at this conference, and he expected that global licensing would be possible due to the high global interest.
Reporter Han Min-soo